Table 2.
Semiquantitative assessment of proportion of CD34+ fibroblasts in tumor stroma of invasive lobular carcinoma of the breast; continuous variables: mean (standard deviation), p values of the t test for association with clinicopathological parameters; categorical variables: absolute (relative) frequencies, p values of the χ2- or Fisher’s exact-tests for association with clinicopathological parameters
| Proportion of CD34+ fibroblasts | Absent n = 49 | Focally present n = 49 | Predominantly present n = 15 | Uniformly present n = 20 | p overall |
|---|---|---|---|---|---|
| Tumor size, in mm | 25.2 (17.5) | 24.3 (18.5) | 14.3 (7.59) | 22.8 (22.0) | 0.219 |
| pT stage | 0.615 | ||||
| pT1a | 2 (4.08%) | 4 (8.16%) | 1 (6.67%) | 2 (10.0%) | |
| pT1b | 4 (8.16%) | 2 (4.08%) | 3 (20.0%) | 4 (20.0%) | |
| pT1c | 21 (42.9%) | 22 (44.9%) | 8 (53.3%) | 8 (40.0%) | |
| pT2 | 16 (32.7%) | 16 (32.7%) | 3 (20.0%) | 3 (15.0%) | |
| pT3 | 4 (8.16%) | 4 (8.16%) | 0 (0.00%) | 3 (15.0%) | |
| pT4b | 2 (4.08%) | 1 (2.04%) | 0 (0.00%) | 0 (0.00%) | |
| Grade | 0.067 | ||||
| G1 | 0 (0.00%) | 2 (4.08%) | 1 (6.67%) | 3 (15.0%) | |
| G2 | 38 (77.6%) | 41 (83.7%) | 10 (66.7%) | 12 (60.0%) | |
| G3 | 11 (22.4%) | 6 (12.2%) | 4 (26.7%) | 5 (25.0%) | |
| Lymph node positivity | 0.004 | ||||
| Yes | 24 (49.0%) | 16 (32.7%) | 1 (6.67%) | 3 (15.0%) | |
| No | 25 (51.0%) | 33 (67.3%) | 14 (93.3%) | 17 (85.0%) | |
| pN stage | 0.006 | ||||
| pN0 | 25 (51.0%) | 33 (67.3%) | 14 (93.3%) | 17 (85.0%) | |
| pN1mi | 2 (4.08%) | 1 (2.04%) | 0 (0.00%) | 1 (5.00%) | |
| pN1a | 3 (6.12%) | 11 (22.4%) | 1 (6.67%) | 0 (0.00%) | |
| pN2a | 11 (22.4%) | 2 (4.08%) | 0 (0.00%) | 1 (5.00%) | |
| pN3a | 7 (14.3%) | 2 (4.08%) | 0 (0.00%) | 1 (5.00%) | |
| pN3b | 1 (2.04%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | |
| Distant metastasis until 12/2018 | 0.231 | ||||
| With metastasis | 14 (33.3%) | 9 (25.7%) | 0 (0.00%) | 3 (23.1%) | |
| Without metastasis | 28 (66.7%) | 26 (74.3%) | 9 (100%) | 10 (76.9%) | |
| Proportion of α SMA myofibroblasts | 0.010 | ||||
| Absent | 12 (24.5%) | 14 (28.6%) | 6 (40.0%) | 13 (65.0%) | |
| Focally present | 12 (24.5%) | 14 (28.6%) | 7 (46.7%) | 5 (25.0%) | |
| Predominantly present | 15 (30.6%) | 16 (32.7%) | 2 (13.3%) | 2 (10.0%) | |
| Uniformly present | 10 (20.4%) | 5 (10.2%) | 0 (0.00%) | 0 (0.00%) | |
| Proportion of α SMA myofibroblasts, dichotomized | 0.010 | ||||
| Absent | 12 (24.5%) | 14 (28.6%) | 6 (40.0%) | 13 (65.0%) | |
| Present | 37 (75.5%) | 35 (71.4%) | 9 (60.0%) | 7 (35.0%) | |
| Morphological ILC subtype | 0.982 | ||||
| Classical ILC | 39 (79.6) | 42 (85.7%) | 13 (86.7%) | 18 (90.0%) | |
| Solid ILC | 1 (2.04%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | |
| Pleomorphic ILC | 1 (2.04%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | |
| Tubulolobular ILC | 7 (14.3%) | 7 (14.3%) | 2 (13.3%) | 2 (10.0%) | |
| Mixed | 1 (2.04%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) | |